Gearing Up for the US Market: PMcardio Showcases at ACC.24
We’re thrilled to share our experience at the American College of Cardiology’s 24th annual meeting (ACC.24) in Atlanta, where we showcased our AI-powered ECG interpretation platform
We’re thrilled to share our experience at the American College of Cardiology‘s 24th annual meeting (ACC.24) in Atlanta, where we showcased our AI-powered ECG interpretation platform, PMcardio, at a U.S. conference for the first time. Our team, including renowned ECG experts Steve Smith, MD, and Pendell Meyers, MD, was on hand to demonstrate how our technology is pushing the boundaries in the diagnosis and treatment of acute heart attacks.
The event was a significant opportunity for us not just to demonstrate our innovations but also to deepen existing relationships and build new ones within the cardio community. It was a pleasure to meet in person with clinical teams from our validation sites in the US that are currently piloting PMcardio in their institutions and to start conversations with potential new partners. These interactions are invaluable as they lay the groundwork for future collaborations that can help us drive even more advancements in cardiac care.
We extend our heartfelt thanks to everyone who stopped by our booth. Your enthusiasm and engagement not only affirm the importance of our work but also fuel our ongoing commitment to enhancing patient care through cutting-edge AI.
As a CE Class II(b) EU Medical Device, we are now looking forward to the next big step: obtaining FDA Medical Device 510(k) Clearance. We anticipate this approval in the coming months, which will mark a major milestone as we prepare to fully enter the US market.
As we reflect on a successful event, we’re excited about the opportunities that lie ahead to further revolutionize the field of cardiology. Keep an eye out for updates on future events and conferences where we’ll be showcasing PMcardio—we look forward to seeing you there!
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
